Form 8-K

0001171843-22-007386.txt : 20221110 0001171843-22-007386.hdr.sgml : 20221110 20221110172101 ACCESSION NUMBER: 0001171843-22-007386 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Predictive Oncology Inc. CENTRAL INDEX KEY: 0001446159 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 331007393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36790 FILM NUMBER: 221378661 BUSINESS ADDRESS: STREET 1: 2915 COMMERS DRIVE, STREET 2: SUITE 900 CITY: EAGAN STATE: MN ZIP: 55121 BUSINESS PHONE: 651-389-4800 MAIL ADDRESS: STREET 1: 2915 COMMERS DRIVE, STREET 2: SUITE 900 CITY: EAGAN STATE: MN ZIP: 55121 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutics Inc. DATE OF NAME CHANGE: 20180314 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutic Inc. DATE OF NAME CHANGE: 20180208 FORMER COMPANY: FORMER CONFORMED NAME: Skyline Medical Inc. DATE OF NAME CHANGE: 20130807 8-K 1 f8k_111022.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2022

_______________________________

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-36790	33-1007393
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2915 Commers Drive, Suite 900

Eagan, Minnesota 55121

(Address of Principal Executive Offices) (Zip Code)

(651) 389-4800

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	POAI	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2022, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the third quarter ended September 30, 2022.

Item 9.01. Financial Statements and Exhibits.

(a) Not applicable.

(b) Not applicable.

(d) Exhibits

Exhibit No.		Description

99.1		Press Release dated November 10, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Predictive Oncology Inc.


Date: November 10, 2022	By:	/s/ Bob Myers
		Bob Myers
		Chief Financial Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

Exhibit 99.1

Predictive Oncology Reports Third Quarter Financial Results

EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include:

Raymond F. Vennare, has been appointed as Chief Executive Officer and Chairman of the Board. An accomplished executive with more than three decades of experience, Mr. Vennare has a long history of building, launching and leading biotech companies.
Predictive Oncology continues to gain traction with potential partners with its breakthrough solution at a pivotal time in drug discovery that enables pharmaceutical and biotech companies to expedite drug development and speed time to market.
The company is leveraging its novel platform technology that has the power to impact a billion-dollar biopharmaceutical landscape in a way that has never been done before. Pairing the largest privately held biobank of more than 150,000 tumor samples with artificial intelligence, Predictive Oncology is able to help drug developers make higher confidence predictions of which molecules will (and won’t ) be successful and ultimately leads to greater chances of commercial success.
Other developments include the announcement that the company’s GMP lab is available for business which opens the opportunity to help clients move from pre-clinical drug development to the investigational new drug (IND) qualification, including phase 1 clinical trials.
The appointment of key team members including strategic advisor Dr. Kamal Egodage who brings over 25 years of experience and has supported over 75 pharmaceutical products to market, as well as the board appointment of Mr. David Smith, a life sciences and intellectual property attorney and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells.

Q3 2022 Financial results

The consolidated reportable segments of Predictive Oncology’s recognized revenue is $455,827 for the quarter, which has increased from $313,663 to the comparative three-month period of 2021, which depicts a revenue growth of 45%.

Helomics reported an improvement in its net losses primarily due to a decrease in impairment charges in 2022.

The gross profit margin has grown during the quarter ended September 30, 2022 to 76% compared to 65% in the comparable 2021 period, which represents a material upward movement of 11%.

Research and development costs reduced to $116,763 in the quarter ended September 30, 2022, from $234,357 in the quarter ended September 30, 2021 which represents a positive change of 50%, due to the consolidation of the company’s lab to Pittsburgh.

General and administrative expenses increased to $3,287,918 for the three months ended September 30, 2022, from $2,061,458 for the three months ended September 30, 2021, which was primarily due to higher payroll resulting from the acquisition of zPREDICTA and costs related to the consolidation of the Massachusetts TumorGenesis division to Pittsburgh and the accrued expenses for the retirement of our CEO.

Operations expenses have increased to $857,130 from $648,935 in the three months ended September 30, 2022 as compared to the same quarter of 2021, primarily due to higher costs related to staff including the increased headcount at zPREDICTA, partially offset by lower research and development expenses .

Net cash used in operating activities was $9,135,812 and $8,464,821 for the nine months ended September 30, 2022, and September 30, 2021, respectively. This represents an incremental increase of 8% as compared to the same period of 2021, primarily because of the increase in working capital. Furthermore, net cash provided by financing activities has substantially dropped to $6,739,031 from $50,378,237, an 87% decrease due to the large cash raises in 2021.

The quarterly sales and marketing expenses have increased to $333,377 in September 2022, from $172,869 in the quarter ended September 2021, driven by increased marketing and business development initiatives in the current year.

The company incurred a net loss of $17,821,524 for the nine months ended September 30, 2022, compared to a $11,900,662 loss for the nine months ended September 30, 2021. The $5,920,862 difference is predominantly due to the goodwill impairment charge of $7,231,093 related to zPREDICTA recognized in 2022 as compared to the goodwill impairment charge of $2,813,792 related to Helomics recognized in 2021. On September 30, 2022, the company had $25,393,738 in cash and cash equivalents.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) is a science-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials.

Forward-Looking Statement:

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2022			December 31, 2021
	(unaudited)			(audited)
ASSETS
Current Assets:
Cash and Cash Equivalents	$	25,393,738		$	28,202,615
Accounts Receivable		324,708			354,196
Inventories		493,722			387,684
Prepaid Expense and Other Assets		645,153			513,778
Total Current Assets		26,857,321			29,458,273

Fixed Assets, net		2,202,102			2,511,571
Intangibles, net		3,701,603			3,962,118
Lease Right-of-Use Assets		329,565			814,454
Other Long-Term Assets		75,618			167,065
Goodwill		-			6,857,790
Total Assets	$	33,166,209			43,771,271

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable	$	917,271		$	1,021,774
Accrued Expenses and other liabilities		1,813,580			1,262,641
Derivative Liability		22,099			129,480
Contract Liabilities		495,365			186,951
Lease Liability		219,763			639,662
Total Current Liabilities		3,468,078			3,240,508

Lease Liability – Net of current portion		5,483			239,664
Other long-term liabilities		99,770			25,415
Total Liabilities		3,573,331			3,505,587

Stockholders’ Equity:
Preferred Stock, 20,000,000 authorized inclusive of designated below
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding		792			792
Common Stock, $.01 par value, 200,000,000 shares authorized, 78,407,473 and 65,614,597 outstanding		784,074			656,146
Additional paid-in capital		174,669,817			167,649,028
Accumulated Deficit		(145,861,805	)		(128,040,282	)
Total Stockholders’ Equity		29,592,878			40,265,684

Total Liabilities and Stockholders’ Equity	$	33,166,209		$	43,771,271

PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS
(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2022			2021			2022			2021
Revenue	$	455,827		$	313,663		$	1,141,986		$	944,187
Cost of goods sold		108,151			110,165			351,669			350,800
Gross profit		347,676			203,498			790,317			593,387

General and administrative expense		3,287,918			2,061,458			8,063,265			7,410,208
Operations expense		857,130			648,935			2,657,314			1,791,543
Sales and marketing expense		333,377			172,869			908,867			447,298
Loss on goodwill impairment		-			2,813,792			7,231,093			2,813,792
Total operating loss		(4,130,749	)		(5,493,556	)		(18,070,222	)		(11,869,454	)
Other income		63,047			58,830			146,524			144,122
Other expense		(2,001	)		(7,413	)		(5,207	)		(244,214	)
Gain (loss) on derivative instruments		10,219			4,122			107,381			68,884
Net loss	$	(4,059,484	)	$	(5,438,017	)	$	(17,821,524	)	$	(11,900,662	)
Net loss attributable to common shareholders per common shares-basic and diluted	$	(4,059,484	)	$	(5,438,017	)	$	(17,821,524	)	$	(11,900,662	)

Loss per common share basic and diluted	$	(0.05	)	$	(0.08	)	$	(0.25	)	$	(0.23	)

Weighted average shared used in computation – basic and diluted		78,383,878			65,406,312			71,084,454			51,272,960

Media relations contact:
Predictive Oncology
Theresa Ferguson
630-566-2003
tferguson@predictive-oncology.com

Investor relations contact:
Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 10, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 10, 2022
Entity File Number	001-36790
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Entity Tax Identification Number	33-1007393
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2915 Commers Drive, Suite 900
Entity Address, City or Town	Eagan
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55121
City Area Code	651
Local Phone Number	389-4800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	POAI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 f8k_111022_htm.xml IDEA: XBRL DOCUMENT 0001446159 2022-11-10 2022-11-10 iso4217:USD shares iso4217:USD shares 0001446159 false 8-K 2022-11-10 Predictive Oncology Inc. DE 001-36790 33-1007393 2915 Commers Drive, Suite 900 Eagan MN 55121 651 389-4800 false false false false Common stock, $0.01 par value POAI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_111022.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_111022.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_111022.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_111022.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_111022.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-007386-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-007386-xbrl.zip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end